Vystar Corporation (OTCBB: VYST) $20M (MarketCap) Explains the Benefits of Natural Rubber Latex

 Here's an interesting statistic: 10% of all condomcommercial product to use Vystar's flagship
users who are exposed to the latex protiensdevelopmental offering. "Vytex is the culmination of
in latex that are added to rubber products areyears of research resulting in a very good natural
allergic and exposed. These users aren't just allergicrubber latex product that maintains all of the good
to the latex in condoms; there are over 40,000properties of latex such as barrier protection and
products that require a latex application, everythingelasticity, and yet, we have been able to remove the
from automotive tires to apparel, to heavy industrialproteins that cause some people to have allergies"
uses like foam. The allergic properties of latex comesaid Mr. Doyle. He went on to talk about market size
from the naturally occurring chemicals that make upand the potential for Vystar's NRL to be included in
the latex in its rawest form: as sap from Southevery industrial application available. "The potential
African and Latin American trees. While there aremarket size is huge, just as a raw material. It is a $3
ways to reduce the allergenic properties of latexbillion market selling to the companies who produce
during production, they cannot be eliminated. Andgloves, condoms, catheters, etc."
that's where Vystar comes in.Checking into the first quarter's earning reveals a
Mr. Doyle gave me a brief history of the demand forcompany with almost no debt and increasing strength
hypoallergenic, or "reduced" allergenic latex, and howin cash flow. Total assets are $1.2M versus $336K in
hard Vystar has been working to provide a solution.total liabilities, a quick ratio of about 3.5; a strong
During the tremulous years of the late 1980's, theindication the company could access credit to finance
AIDS crisis was gaining recognition and healthcaregrowth in the future. Total revenues were $83K for
professionals had been required to begin wearingthe first quarter 2010 compared with only $11K for
those ubiquitous latex gloves when treating patients,the same period in 2009, attributable to sales of the
leading to a huge explosion of latex glove productionEnvy condom.
in Southeast Asia, a region not particularly known forSo how's business?
its quality production levels. The factories ignored"We have a solid core of investors in the healthcare
standard western safety procedures that involvedarena. We've never taken a loan, we've never
how the latex is washed, processed, and droppedworked with any venture capital groups, and we're
into the product, sparking a wave ofdoing very well in the financing area". For a company
allergy-connected health issues during the 90's andpreparing to tackle such huge market potential, those
today.are the exact qualities others would be Envious for.
Mr. Doyle said the issue has been getting better asTo watch a video on the Business News Network
production quality improves, but the need for Vytexthat my conversation with Mr. Doyle was based off
NRL is obvious. The Envy condom received FDAof, click here.
501(k) clearance in 2009 and became the first